TITLE

Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists

AUTHOR(S)
Wallis, R. S.; Broder, M. S.; Wong, J. V.; Hanson, M. E.; Beenhouwer, D. O.
PUB. DATE
May 2004
SOURCE
Clinical Infectious Diseases;5/1/2004, Vol. 38 Issue 9, p1261
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food and Drug Administration for January 1998-September 2002. Granulomatous infections were reported at rates of ∼239 per 100,000 patients who received infliximab and ∼74 per 100,000 patients who received etanercept (P < .001). Tuberculosis was the most frequently reported disease, occurring in `&sim144 and ∼35 per 100,000 infliximab- treated and etanercept-treated patients, respectively (P< .001). Candidiasis, coccidioidomycosis,histoplasmosis, listeriosis, nocardiosis, and infections due to nontuberculous mycobacteria were reported with significantly greater frequency among infliximab-treated patients. Seventy-two percent of these infection occurred ≤90 days after starting infliximab treatment, and 28% occurred after starting etanercept treatment (P < .001). These data indicate a risk of granulomatous infection that was 3.25-fold greater among patients who received infliximab than among those who received etanercept. The clustering of reports shortly after initiation of treatment with infliximab is consistent with reactivation of latent infection.
ACCESSION #
13058675

 

Related Articles

  • Mycobacterial and Other Serious Infections in Patients Receiving Anti-Tumor Necrosis Factor and Other Newly Approved Biologic Therapies: Case Finding through the Emerging Infections Network. Winthrop, Kevin L.; Yamashita, S.; Beekmann, S. E.; Polgreen, P. M. // Clinical Infectious Diseases;6/1/2008, Vol. 46 Issue 11, p1738 

    We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Non-tuberculous mycobacterial infections, histoplasmosis, and...

  • Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Thomas, John E.; Taoka, Christy R.; Gibbs, Barnett T.; Fraser, Susan L. // Hawaii Medical Journal;Jan2006, Vol. 65 Issue 1, p12 

    A case of fatal pulmonary Mycobacterium abscessus infection in a 56-year-old man is reported. The patient had a longstanding history of seropositive, nodular rheumatoid arthritis with severe joint manifestations that had been treated with a regimen of prednisone, leflunomide, and etanercept. He...

  • Tuberculosis and anti-TNF-α treatment. Ormerod, L. P. // Thorax;Nov2004, Vol. 59 Issue 11, p921 

    This article presents information about the connections between anti-tumor necrosis factor (TNF) and tuberculosis (TB). The increase in active TB in association with anti-TNF-α treatment has led to a requirement for patient screening for active and latent TB before anti-TNF treatment is...

  • Neutralization of Tumor Necrosis Factor (TNF) by Antibody but not TNF Receptor Fusion Molecule Exacerbates Chronic Murine Tuberculosis. Plessner, Hillarie L.; Lin, P. Ling; Kohno, Tadahiko; Louie, James S.; Kirschner, Denise; Chan, John; Flynn, JoAnne L. // Journal of Infectious Diseases;6/1/2007, Vol. 195 Issue 11, p1643 

    Tumor necrosis factor (TNF) plays an essential role in the immunologic maintenance of Mycobacterium tuberculosis infection. Although an increased rate of tuberculosis has been reported in humans treated with anti-TNF biological agents, disparate rates of disease have been observed between those...

  • High Heritability of Antimycobacterial Immunity in an Area of Hyperendemicity for Tuberculosis Disease. Cobat, Aurelie; Gallant, Caroline J.; Simkin, Leah; Black, Gillian F.; Stanley, Kim; Hughes, Jane; Doherty, T. Mark; Hanekom, Willem A.; Eley, Brian; Beyers, Nulda; Jaïs, Jean-Philippe; van Helden, Paul; Abel, Laurent; Hoal, Eileen G.; Alcaïs, Alexandre; Schurr, Erwin // Journal of Infectious Diseases;1/1/2010, Vol. 201 Issue 1, p15 

    Human antimycobacterial immunity is a critical component of tuberculosis (TB) pathogenesis that is often used to infer the presence of TB infection. We report high heritability (>50%) for in vitro secretion of tumor necrosis factor α and interferon γ (IFN-γ), and the frequency of...

  • LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. Haraguchi, Soichi; Day, Noorbibi K; Kamchaisatian, Wasu; Beigier-Pompadre, Macarena; Stenger, Steffen; Tangsinmankong, Nutthapong; Sleasman, John W; Pizzo, Salvatore V; Cianciolo, George J // AIDS Research & Therapy;2006, Vol. 3, p1 

    Background: Co-infections of human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (M. Tb) are steadily increasing and represent a major health crisis in many developing countries. Both pathogens individually stimulate tumor necrosis factor-alpha (TNF) release from infected cells and...

  • Macrophages Play a Dual Role during Pulmonary Tuberculosis in Mice. Leemans, Jaklien C.; Thepen, Theo; Weijer, Sebastiaan; Florquin, Sandrine; Van Rooijen, Nico; Van de Winkel, Jan G.; Van der Poll, Tom // Journal of Infectious Diseases;1/1/2005, Vol. 191 Issue 1, p65 

    Pulmonary macrophages provide the preferred hiding and replication site of Mycobacterium tuberculosis but display antimicrobial functions. This raises questions regarding the role of macrophages during tuberculosis. We depleted lungs of activated macrophages (activated macrophage mice) and...

  • Modulation of Infection with Histoplasma capsulatum by Inhibition of Tumor Necrosis Factor-α Activity. Deepe, Jr., George S. // Clinical Infectious Diseases;8/1/2005 Supplement, Vol. 41, pS204 

    Tumor necrosis factor (TNF)-α is required for host defenses against a number of pathogenic microbes, including Histoplasma capsulatum. In mice, TNF-α is necessary for the generation of a protective immune response to both primary and secondary histoplasmosis. Recent reports indicate that,...

  • Prevention, awareness key. Tanzola, Melinda // Dermatology Times;Sep2006 Supplement, Vol. 27, ps13 

    The article discusses on the therapeutic role as well as the side effects of tumor necrosis factor (TNF) inhibitors. The drugs are used in the treatment of rheumatoid arthritis, refractory Crohn's disease, and psoriasis. However, patients taking TNF inhibitors are at great risk for infection of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics